PharmaMar announces abstracts to be presented at
ASCO 2020

Madrid, May 14th, 2020.- PharmaMar (MSE:PHM) has announced today that it will present, together with its partners, seven new posters from various clinical studies with lurbinectedin and Yondelis® (trabectedin) at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29th to June 2nd, 2020.

In particular, the data obtained from two clinical studies with lurbinectedin will be presented. One will present updated data from the Phase Ib-II trial of lurbinectedin in combination with irinotecan in advanced solid tumors; and the other will show the results of the safety analysis of lurbinectedin in monotherapy against topotecan, with the data obtained from the Phase III CORAIL trial and the Phase II basket trial with lurbinectedin.

Various studies conducted with trabectedin will also be presented, these include an oral session, in which the final data from the Phase II study of trabectedin in combination with doxorubicin for treating patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS) will be presented.

All ASCO virtual poster presentations will be available to registered participants, on request for 180 days from May 29th, 2020: https://meetinglibrary.asco.org/

Highlighted studies at ASCO 2020

Lurbinectedin

- Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors. Updated results from a phase Ib-II trial.
  Poster discussion: Poster number 244 (Abstract 3514)
  Lead Author: Santiago Ponce Aix, Hospital Universitario 12 De Octubre, Madrid (Spain).

- Pooled safety analysis of single-agent lurbinectedin versus topotecan (results from a randomized phase III trial CORAIL and a phase II Basket trial).
  Poster number 365 (Abstract 3635)
Yondelis® (trabectedin)

- A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study. 
  Oral Abstract Session. (Abstract 11506)
  Lead Author: Patricia Pautier, Medical Oncology Department, Institut Gustave Roussy, Villejuif, France.

- Trabectedin and RAdiotherapy in Soft-Tissue Sarcoma (TRASTS) study: an international, prospective, phase II trial. A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) group study.
  Poster discussion: Poster number 402 (Abstract 11514)
  Lead Author: Alessandro Gronchi, Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

- Which patients with pre-treated locally advanced or metastatic sarcoma benefit most from trabectedin treatment: First results of a retrospective study of the German Interdisciplinary Sarcoma Group (GISG-14 - ReTraSarc).
  Poster number 442 (Abstract 11554)
  Lead Author: Daniel Pink, Helios Klinikum Bad Saarow-Sarcoma Center Berlin-Brandenburg and University Medicine Greifswald, Germany.

- Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study.
  Poster number 434 (Abstract 11546)
  Lead Author: David Silva Moura, Group of Advanced Therapies and Biomarkers in Sarcomas, Institute of Biomedicine of Seville, Ibis/Hospital Universitario Virgen Del Rocío/Csic/Universidad De Sevilla, Seville, Spain.
Cardiac Safety of Trabectedin Monotherapy or in Combination with Pegylated Liposomal Doxorubicin in Patients with Sarcomas and Ovarian Cancer.

Poster number 435 (Abstract 11547)

Lead Author: Robin Lewis Jones, Royal Marsden Hospital/Institute of Cancer Research, London, United Kingdom.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

About Yondelis®

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000
Capital Markets & Investor Relations:
José Luis Moreno – Capital Markets & Investor Relations Director
María Marín de la Plaza – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at www.pharmamar.com